<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Bufadienolides, known ligands of the <z:chebi fb="199" ids="26708">sodium</z:chebi> pump, have been shown to inhibit the proliferation of several <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cell types </plain></SENT>
<SENT sid="1" pm="."><plain>However, their development to date as anticancer agents has been impaired by a narrow therapeutic margin resulting from their potential to induce cardiotoxicity </plain></SENT>
<SENT sid="2" pm="."><plain>In the present study, we examined the effects of <z:chebi fb="0" ids="16990">bilirubin</z:chebi>, an endogenous <z:chebi fb="11" ids="22586">antioxidant</z:chebi>, on the cardiotoxicity of bufadienolides (derived from toad venom) in guinea-pigs </plain></SENT>
<SENT sid="3" pm="."><plain>The results showed that bufadienolides (8 mg/kg) caused <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo>, conduction block, cardiac dysfunction and <z:hpo ids='HP_0011420'>death</z:hpo> in guinea-pigs </plain></SENT>
<SENT sid="4" pm="."><plain>Pretreatment with <z:chebi fb="0" ids="16990">bilirubin</z:chebi> (75 and 150 mg/kg) significantly prevented bufadienolide-induced premature ventricular complexes, <z:hpo ids='HP_0004756'>ventricular tachycardia</z:hpo>, <z:hpo ids='HP_0001663'>ventricular fibrillation</z:hpo> and <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="0" ids="16990">Bilirubin</z:chebi> also markedly improved the inhibition of cardiac contraction in bufadienolide-treated guinea-pigs as evidenced by increases in left ventricular systolic pressure and decreases in left ventricular diastolic pressure in vivo </plain></SENT>
<SENT sid="6" pm="."><plain>Furthermore, <z:chebi fb="0" ids="16990">bilirubin</z:chebi> significantly reduced the intracellular <z:chebi fb="199" ids="26708">sodium</z:chebi> content ([<z:chebi fb="0" ids="29101">Na(+)</z:chebi>]( i )) in ex vivo bufadienolide-stimulated guinea-pig ventricular myocytes loaded with the <z:chebi fb="199" ids="26708">sodium</z:chebi> indicator <z:chebi fb="199" ids="26708">Sodium</z:chebi> Green </plain></SENT>
<SENT sid="7" pm="."><plain>An antitumor study showed that <z:chebi fb="0" ids="16990">bilirubin</z:chebi> did not compromise the ability of bufadienolides to inhibit <z:hpo ids='HP_0012126'>gastric cancer</z:hpo> cell MGC-803 proliferation </plain></SENT>
<SENT sid="8" pm="."><plain>These results suggested that <z:chebi fb="0" ids="16990">bilirubin</z:chebi> can attenuate bufadienolide-induced <z:hpo ids='HP_0011675'>arrhythmias</z:hpo> and cardiac dysfunction in guinea-pigs by reducing elevated [<z:chebi fb="0" ids="29101">Na(+)</z:chebi>]( i ) and may improve bufadienolide therapeutic index in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> treatment </plain></SENT>
</text></document>